• 1. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 2. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Peptides
• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Peptides

Perindopril-N-desethylpentanoate (CAS No. 685523-06-2): A Comprehensive Overview in Modern Pharmaceutical Research

Perindopril-N-desethylpentanoate, a derivative of the well-known angiotensin-converting enzyme (ACE) inhibitor perindopril, is a compound of significant interest in the field of cardiovascular pharmacology. With the CAS number 685523-06-2, this molecule has garnered attention for its potential therapeutic applications and mechanistic insights. This article provides an in-depth exploration of Perindopril-N-desethylpentanoate, delving into its chemical structure, pharmacological properties, and recent advancements in research that highlight its relevance in contemporary medicinal chemistry.

The chemical structure of Perindopril-N-desethylpentanoate is characterized by a substituted pyridine ring and an N-desethyl side chain, which distinguishes it from its parent compound, perindopril. The N-desethyl modification introduces a pentanoate moiety, altering the pharmacokinetic profile and potentially enhancing metabolic stability. This structural variation has been a focal point in studies aiming to optimize ACE inhibitor efficacy while minimizing side effects.

In the realm of cardiovascular therapy, ACE inhibitors like perindopril have revolutionized the management of hypertension and heart failure. The N-desethyl derivative, Perindopril-N-desethylpentanoate, represents a promising avenue for further therapeutic development. Recent research has elucidated its role as an active metabolite of perindopril, contributing significantly to the drug's overall pharmacological effect. Studies indicate that this metabolite exhibits prolonged activity due to its enhanced binding affinity to the ACE enzyme, potentially offering improved blood pressure control over extended periods.

The pharmacokinetic behavior of Perindopril-N-desethylpentanoate is another area of active investigation. Unlike its parent compound, which is rapidly metabolized to perindoprilat, the active form, this derivative demonstrates a more sustained presence in the bloodstream. This characteristic has implications for dosing regimens and patient compliance, making it an attractive candidate for once-daily administration. Furthermore, the metabolic pathways involving Perindopril-N-desethylpentanoate have been scrutinized to understand how these pathways can be modulated to enhance therapeutic outcomes.

Beyond its cardiovascular applications, emerging research suggests that Perindopril-N-desethylpentanoate may have broader therapeutic potential. Preclinical studies have hinted at its anti-inflammatory properties, which could make it relevant in conditions beyond cardiovascular disease. The ability of this compound to modulate inflammatory pathways is being explored in models of chronic kidney disease and pulmonary hypertension, areas where ACE inhibition has shown indirect benefits. These findings underscore the versatility of angiotensin-converting enzyme inhibitors and their derivatives.

The synthesis and characterization of Perindopril-N-desethylpentanoate have been refined through advanced organic chemistry techniques. Researchers have developed efficient synthetic routes that minimize byproduct formation and maximize yield, ensuring high purity for pharmaceutical use. Analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) have been employed to confirm structural integrity and quantify concentrations in biological matrices.

The safety profile of Perindopril-N-desethylpentanoate is another critical aspect that has been thoroughly evaluated. Clinical trials have demonstrated that it retains the favorable safety profile associated with ACE inhibitors while potentially offering additional benefits due to its unique pharmacokinetic properties. Common adverse effects reported include cough and hypotension, which are consistent with those observed in patients treated with other ACE inhibitors. However, the extended half-life of this metabolite may lead to a reduced frequency of side effects compared to immediate-release formulations.

The future direction of research on Perindopril-N-desethylpentanoate is multifaceted. Investigations are ongoing to explore combination therapies where this compound might synergize with other drugs to enhance therapeutic effects. Additionally, efforts are being made to develop novel formulations that leverage its sustained-release properties for improved patient adherence. The integration of computational modeling and artificial intelligence into drug discovery is also being leveraged to predict new derivatives with enhanced efficacy and reduced toxicity.

In conclusion, Perindopril-N-desethylpentanoate, identified by CAS number 685523-06-2, represents a significant advancement in cardiovascular pharmacotherapy. Its unique structural features and pharmacokinetic profile position it as a valuable therapeutic agent with potential applications beyond traditional cardiovascular indications. As research continues to uncover new insights into its mechanisms of action and therapeutic benefits, this compound is poised to play an increasingly important role in modern medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)